Fierce Pharma Asia—Ivonescimab's survival win; Fosun, Sitala's $670M deal; HutchMed's acting CEO 0 28.08.2025 18:36 Fiercepharma.com Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immune disease candidate. Hutchmed's CEO took medical leave. And more. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
